BALPHARMAPharmaceuticals
Bal Pharma Ltd — Cash Flow Statement
₹60.42
-1.51%
Bal Pharma Ltd Cash Flow Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Free Cash Flow | 1.53 Cr | 11.83 Cr | -16.18 Cr | 18.33 Cr | — |
| Repayment Of Debt | -4.95 Cr | — | — | — | -3.66 Cr |
| Issuance Of Debt | 0.00 | 5.83 Cr | 11.70 Cr | 3.08 Cr | — |
| Issuance Of Capital Stock | 0.14 Cr | 0.50 Cr | 3.92 Cr | 0.91 Cr | — |
| Capital Expenditure | -18.79 Cr | -10.98 Cr | -14.65 Cr | -8.47 Cr | — |
| End Cash Position | 1.75 Cr | 4.20 Cr | 1.49 Cr | 1.11 Cr | — |
| Other Cash Adjustment Outside Changein Cash | 1000.00 | 1000.00 | 1000.00 | -1000.00 | — |
| Beginning Cash Position | 4.20 Cr | 1.49 Cr | 1.11 Cr | 1.02 Cr | — |
| Effect Of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Changes In Cash | -2.44 Cr | 2.71 Cr | 0.37 Cr | 0.09 Cr | — |
| Financing Cash Flow | -7.84 Cr | -1.21 Cr | 24.09 Cr | -17.22 Cr | — |
| Interest Paid Cff | -16.85 Cr | -16.33 Cr | -13.68 Cr | -10.40 Cr | — |
| Cash Dividends Paid | -1.91 Cr | -1.57 Cr | -1.56 Cr | -1.48 Cr | — |
| Net Common Stock Issuance | 0.14 Cr | 0.50 Cr | 3.92 Cr | 0.91 Cr | — |
| Common Stock Issuance | 0.14 Cr | 0.50 Cr | 3.92 Cr | 0.91 Cr | — |
| Net Issuance Payments Of Debt | 10.78 Cr | 16.19 Cr | 35.42 Cr | -6.25 Cr | — |
| Net Short Term Debt Issuance | 15.73 Cr | 10.36 Cr | 23.72 Cr | -9.33 Cr | — |
| Net Long Term Debt Issuance | -4.95 Cr | 5.83 Cr | 11.70 Cr | 3.08 Cr | — |
| Long Term Debt Payments | -4.95 Cr | — | — | — | -3.66 Cr |
| Long Term Debt Issuance | 0.00 | 5.83 Cr | 11.70 Cr | 3.08 Cr | — |
| Investing Cash Flow | -14.92 Cr | -18.89 Cr | -22.18 Cr | -9.48 Cr | — |
| Interest Received Cfi | 0.74 Cr | 0.69 Cr | 0.14 Cr | 0.18 Cr | — |
| Net Investment Purchase And Sale | 3.13 Cr | -8.61 Cr | -0.81 Cr | -1.19 Cr | — |
| Net Business Purchase And Sale | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Purchase Of Business | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Net PPE Purchase And Sale | -18.79 Cr | -10.97 Cr | -14.65 Cr | -8.47 Cr | — |
| Sale Of PPE | 0.00 | 0.01 Cr | — | 0.00 | 0.02 Cr |
| Purchase Of PPE | -18.79 Cr | -10.98 Cr | -14.65 Cr | -8.47 Cr | — |
| Operating Cash Flow | 20.32 Cr | 22.81 Cr | -1.54 Cr | 26.80 Cr | — |
| Taxes Refund Paid | -2.08 Cr | -4.54 Cr | -0.50 Cr | -1.20 Cr | — |
| Change In Working Capital | -7.49 Cr | -4.04 Cr | -27.52 Cr | 1.66 Cr | — |
| Change In Other Current Liabilities | -0.61 Cr | -0.72 Cr | 10.65 Cr | 1.45 Cr | — |
| Change In Other Current Assets | -3.81 Cr | 1.04 Cr | -2.18 Cr | 1.82 Cr | — |
| Change In Payable | 4.17 Cr | -0.60 Cr | 27.17 Cr | 20.59 Cr | — |
| Change In Inventory | -15.21 Cr | 10.19 Cr | -23.61 Cr | -14.01 Cr | — |
| Change In Receivables | 7.18 Cr | -14.29 Cr | -39.84 Cr | -8.94 Cr | — |
| Other Non Cash Items | 14.77 Cr | 14.03 Cr | 11.63 Cr | 7.72 Cr | — |
| Stock Based Compensation | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Provisionand Write Offof Assets | 0.00 | 0.19 Cr | 0.18 Cr | 0.16 Cr | — |
| Depreciation And Amortization | 9.77 Cr | 10.07 Cr | 9.13 Cr | 9.04 Cr | — |
| Depreciation | 9.77 Cr | 10.07 Cr | 7.16 Cr | 7.57 Cr | — |
| Net Foreign Currency Exchange Gain Loss | 0.21 Cr | -1.04 Cr | 0.82 Cr | -0.61 Cr | — |
| Gain Loss On Sale Of PPE | 0.00 | -0.08 Cr | -0.03 Cr | -1.23 Cr | — |
| Net Income From Continuing Operations | 5.14 Cr | 9.05 Cr | 4.75 Cr | 9.18 Cr | — |
| Net Other Financing Charges | — | 2000.00 | 0.48 Cr | 1000.00 | 3.71 Cr |
| Amortization Cash Flow | — | 3.92 Cr | 1.97 Cr | 1.47 Cr | 1.19 Cr |
| Net Other Investing Changes | — | — | -1000.00 | — | 0.03 Cr |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Bal Pharma Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.